Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_4
1
17%
Ph phase_2
2
33%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Recruiting2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

withdrawn117%
active_not_recruiting117%
completed233%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_3

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

NCT04563520
recruitingphase_2

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

NCT07032792
completedphase_3

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

NCT02764489
withdrawnphase_2

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

NCT05020483
active_not_recruitingphase_4

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

NCT04205175
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04563520Phase 3

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Recruiting
NCT07032792Phase 2

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

Recruiting
NCT02764489Phase 3

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Completed
NCT05020483Phase 2

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

Withdrawn
NCT04205175Phase 4

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Active Not Recruiting
NCT02577614Phase 1

FEIBA and Use of Blood Products in Cardiac Surgery

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6